TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07246863: Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Sponsor: CatalYm GmbH · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 131 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07246863 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07246863 Rescue Dossier →